Rigel Pharmaceuticals, Inc.
RIGL
$19.41
$0.130.67%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 15.46% | 1,305.92% | 87.51% | -1,219.00% | 112.95% |
| Total Depreciation and Amortization | -1.15% | -0.33% | 53.25% | 36.52% | 0.34% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.23% | 7.72% | -51.94% | 215.36% | -13.93% |
| Change in Net Operating Assets | -136.05% | 469.39% | 21.24% | 76.28% | -496.99% |
| Cash from Operations | -33.10% | 7,078.48% | 106.02% | 19.66% | -359.16% |
| Capital Expenditure | -160.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 176.92% | -- | -- | -- | 400.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -389.49% | -65.36% | 3,391.69% | 104.48% | -485.91% |
| Cash from Investing | -387.06% | -65.21% | 3,391.69% | 104.55% | -487.52% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 827.22% | -37.30% | 183.15% | -81.69% | 5,300.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -896.02% | 61.40% | -- | 100.00% |
| Cash from Financing | 114.89% | -1,208.78% | 70.06% | -616.87% | 155.93% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -67.68% | 49.24% | 245.30% | 42.89% | -271.63% |